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ABSTRACT 28 
Feto-placental glucocorticoid overexposure is a significant mechanism underlying fetal growth 29 
restriction and the programming of adverse health outcomes in the adult. Placental 30 
glucocorticoid inactivation by 11-hydroxysteroid dehydrogenase type 2 (11β-HSD2) plays a 31 
key role. We previously discovered that Hsd11b2-/- mice, lacking 11β-HSD2, show marked 32 
underdevelopment of the placental vasculature. We now explore the consequences for fetal 33 
cardiovascular development and whether or not this is reversible. We studied Hsd11b2+/+, 34 
Hsd11b2+/- and Hsd11b2-/- littermates from heterozygous (Hsd11b+/-) matings at embryonic day 35 
(E)14.5 and E17.5, where all three genotypes were present to control for maternal effects. Using 36 
high-resolution ultrasound umbilical vein blood velocity in Hsd11b2-/- fetuses did not undergo 37 
the normal gestational increase seen in Hsd11b2+/+ littermates. Similarly, the resistance index 38 
in the umbilical artery did not show the normal gestational decline. Surprisingly, given that 39 
11β-HSD2 absence is predicted to initiate early maturation, the E/A wave ratio was reduced at 40 
E17.5 in Hsd11b2-/- fetuses, suggesting impaired cardiac function. Pravastatin administration 41 
from E6.5, which increases placental VEGFA and thus vascularization, increased placental 42 
fetal capillary volume, ameliorated the aberrant umbilical cord velocity, normalized fetal 43 
weight and improved the cardiac function of Hsd11b2-/- fetuses. This improved cardiac function 44 
occurred despite persisting indications of increased glucocorticoid exposure in the Hsd11b2-/- 45 
fetal heart. Thus, the pravastatin-induced enhancement of fetal capillaries within the placenta 46 
and the resultant hemodynamic changes correspond with restored fetal cardiac function. Statins 47 
may represent a useful therapeutic approach to intrauterine growth retardation due to placental 48 
vascular hypofunction.   49 
 3 
SIGNIFICANCE STATEMENT: 50 
Environmental challenges in utero perturb fetal growth and alter subsequent adult health 51 
outcomes. The role of the placenta is uncertain. We use a genetically modified mouse model of 52 
feto-placental glucocorticoid excess which exhibits decreased placental vascularity and fetal 53 
growth restriction. We show that this associates with retarded fetal heart development. 54 
Strikingly, treatment with pravastatin restores placental vascularity and reverses retarded fetal 55 
growth and cardiovascular development. These results highlight the potential of statins to 56 
remedy placental vascular insufficiency and enhance fetal outcomes in compromised 57 
pregnancy.  58 
 4 
INTRODUCTION  59 
Low birth weight is associated with an increased risk of cardiometabolic disorders in adulthood 60 
(1). Frequently underlying this association is elevated fetal exposure to ‘stress hormones’ - 61 
glucocorticoids. Endogenous glucocorticoids (cortisol in humans, corticosterone in rodents) are 62 
a key signal in late gestation, which alter developmental trajectories of fetal tissues, 63 
predominantly from a proliferative to differentiated state, in preparation for extra-uterine life 64 
(2). Fetal overexposure to glucocorticoids in humans, primates and rodents is detrimental for 65 
placental and fetal growth and development, and ‘programs’ higher risk of cardiometabolic 66 
disease in later life (3-8). Recent data suggest that the detrimental effects of excess 67 
glucocorticoids on fetal growth and development result from direct glucocorticoid actions on 68 
the placenta as well as on the fetus itself (9, 10).  69 
 70 
The fetus and the placenta are maintained in a low glucocorticoid environment by the abundant 71 
expression of feto-placental 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2), an enzyme 72 
which inactivates the much higher levels of glucocorticoids arriving from the maternal 73 
circulation (11, 12). In humans and in animal models, placental 11β-HSD2 expression is 74 
reduced in adverse situations including poor maternal nutrition or maternal stress (13-15). 75 
Bypass of this protective enzyme, be it through synthetic glucocorticoids which are poor 76 
substrates (9, 16), inhibition (by liquorice) or genetic ablation of Hsd11b2 which encodes 11β-77 
HSD2 (10), reduces placental weight. This is accompanied by reduced fetal capillary volume, 78 
surface area density, length and diameter in the placental labyrinth zone. Underlying these 79 
placental changes is a striking reduction in placental expression of vascular endothelial growth 80 
factor (VEGF)–A (9, 10) a major driver of placental angiogenesis. 81 
 82 
Recent evidence suggests that altered placental function, including its haemodynamics, has a 83 
direct impact on the development of fetal organs, particularly the heart (17-22). If compromised 84 
placental vascular development due to glucocorticoid excess can be rescued, this raises the 85 
possibility of a treatment for adverse effects of placental dysfunction upon the fetal heart and 86 
circulation. We therefore assessed placental and umbilical blood velocity and heart growth and 87 
function in Hsd11b2-/- fetuses and then took advantage of the placental VEGF-releasing effects 88 
of pravastatin (23) to determine whether it might rescue or ameliorate the effects of fetal 89 
glucocorticoid over-exposure. 90 
 91 
RESULTS 92 
Hsd11b2-/- fetuses fail to show the normal gestational maturation in umbilical cord blood 93 
velocity and fetal heart function.  94 
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To evaluate maturational changes in umbilical cord blood velocity and heart function, fetuses 95 
of all 3 genotypes from male and female Hsd11b2+/- matings underwent ultrasound analyses at 96 
E14.5 (maximum of labyrinth zone 11β-HSD2 expression (11, 12) and before fetal adrenal 97 
gland steroidogenesis starts (24)), and at E17.5, (as placental 11β-HSD2 falls, around peak fetal 98 
plasma glucocorticoid levels, and just prior to birth, typically E18.5 in Hsd11b2+/- mice (10)). 99 
Umbilical vein blood velocity normally increases over gestation, as exemplified by the 1.4-fold 100 
increase between E14.5 and E17.5 in wild type (Hsd11b2+/+) fetuses (Fig 1A). Although not 101 
different from control littermates at E14.5, umbilical vein blood velocity in Hsd11b2-/- fetuses 102 
did not undergo the normal gestational increase, such that by E17.5 umbilical vein blood 103 
velocity was 24% less than wild-type (Fig 1A). Similarly, the normal gestation decline in 104 
umbilical artery resistance (Resistance Index; RI=systole/[systole+diastole]), apparent in 105 
Hsd11b2+/+ and Hsd11b2+/- fetuses (18% decrease between E14.5 and E17.5) did not occur in 106 
Hsd11b2-/- fetuses (Fig 1B). Thus, there was an interaction between gestational age and 107 
genotype for both umbilical vein blood velocity and RI. Heart function matures between E14.5 108 
and E17.5, and as the fetal heart becomes more compliant, left ventricle (LV) filling becomes 109 
more dependent on passive filling (the E wave) and less dependent on LV filling due to active 110 
contraction of the atria (the A wave) (25). This clearly occurs in both Hsd11b2+/+ and 111 
Hsd11b2+/- fetuses but did not occur in Hsd11b2-/- fetal hearts (Fig 1C). In contrast, myocardial 112 
performance index, a combined measure of systolic and diastolic function (25), was unaltered 113 
by genotype (see Table S1 for myocardial performance index and a breakdown of each of the 114 
cardiac components assessed by ultrasound).  115 
 116 
These functional changes were not due to altered gross morphology of the heart. Thus at E17.5 117 
there were no differences in overall cardiac volume (Hsd11b2+/+: 3.9±0.1, Hsd11b2+/-: 3.8±0.2, 118 
Hsd11b2-/-: 3.4±0.3 mm3) or number of cardiomyocytes (Hsd11b2+/+: 4.1±0.3, Hsd11b2+/-: 119 
4.1±0.2, Hsd11b2-/-: 3.8±0.1 x106). Perhaps analogously, cardiac function is altered in the 120 
absence of gross morphological alteration in mice with cardiomyocyte and vascular smooth 121 
muscle-specific deletion of the glucocorticoid receptor (GR) (26).   122 
 123 
Altered blood velocity in the Hsd11b2-/- umbilical cord prompted us to explore whether this 124 
could be attributed to altered umbilical cord structure or function. Histology revealed no 125 
significant differences between Hsd11b2+/+ and Hsd11b2-/- in luminal area or wall thickness of 126 
the umbilical artery or vein (Table S2). Functionally, isolated umbilical arteries from Hsd11b2-127 
/-mice tended to be more responsive to vasoconstrictors and have lower basal release of 128 
endothelium-dependent mediators. With loss of Hsd11b2 there was no significant alteration in 129 
maximal contractile response to high potassium (Fig 2B) while the thromboxane agonist, 130 
U46619 reduced maximal contractile response (Fig 2C). The maximal contraction (Kmax) to 131 
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U46619 was significantly lower in vessels from Hsd11b2-/- compared to controls (2.41±0.24 132 
mN vs 3.61±0.45 mN, respectively), although the sensitivity to U46619 (EC50) did not differ 133 
between genotypes.  Basal endothelial function (basal release of nitric oxide and prostacyclin) 134 
was explored through contractile response to L-NAME and indomethacin in the presence of an 135 
EC50 dose of U46619. L-NAME + indomethacin caused a further 25-50% transient contraction 136 
of vessels ~ 2 min after addition, returning to baseline with 5 min (Fig 2D). The contractile 137 
response was greatest in the umbilical arteries from control fetuses and lowest in arteries from 138 
Hsd11b2-/- (19±2% vs ±39±7%, p<0.05). Acetylcholine, an endothelium-dependent 139 
vasodilator, did not relax umbilical arteries (Fig S1). The ability of umbilical arteries to relax 140 
to other vasodilators was confirmed by a concentration-dependent relaxation response to the 141 
nitric oxide donor drug, sodium nitroprusside (Fig 2E), with no differences in response between 142 
genotypes. This pattern of response concurs with the in vivo findings. While increased umbilical 143 
artery vasoconstriction and reduced endothelium-dependent functions likely contribute to 144 
reduced fetal blood supply in 11β-HSD2 null fetuses, the differences between genotypes and 145 
magnitude of the changes were modest and other factors are likely also to be involved (ie. 146 
vascular resistance).  147 
 148 
Gene expression patterns in Hsd11b2−/− fetal hearts reflect glucocorticoid overexposure 149 
and earlier maturation. 150 
To investigate glucocorticoid exposure and probe mechanism underlying altered cardiac 151 
function in Hsd11b2-/- fetuses, we measured levels of mRNA encoding glucocorticoid-152 
responsive genes as well as genes important for contractile function. Cardiac expression of 153 
Tsc22d3 (also known as glucocorticoid-induced leucine zipper; GILZ, a mediator of anti-154 
inflammatory and perhaps other glucocorticoid actions) expression exhibited a normal 155 
gestational increase (26) in Hsd11b2+/+ and Hsd11b2+/- fetuses (Fig 3A). Hsd11b2-/- fetuses 156 
(gestational age and genotype interaction,) had elevated levels at E14.5, consistent with higher 157 
glucocorticoid exposure in mid-gestation. Expression of Myh6 (encoding myosin heavy chain-158 
, MYHC, the major contractile protein in the adult heart) normally increases between E14.5 159 
and E17.5 (26), as exemplified by the 1.7-fold increase between E14.5 and E17.5 in Hsd11b2+/+ 160 
and Hsd11b2+/- fetal hearts (Fig 3B). While this gestational increase was exaggerated in 161 
Hsd11b2-/- fetuses, Myh6 mRNA levels reduced (58%) at E14.5 and increased 1.4-fold at E17.5 162 
compared with Hsd11b2+/+ littermates (Fig 3B). A similar pattern of expression was observed 163 
for the Atp2a2 gene encoding the calcium-handling protein SERCA2a (Fig 3C). The 164 
downregulation of both Myh6 and SERCA2a genes at E14.5 appears at variance with higher 165 
glucocorticoid exposure of Hsd11b2-/- fetuses, predicted to cause early cardiac maturation. This 166 
raises the possibilities that either premature glucocorticoid exposure fails to mimic the normal 167 
maturational effects of glucocorticoids upon the heart, or that indirect dysmaturational effects 168 
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predominate. Secretion of cardiac natriuretic peptide A (ANP; encoded by Nppa) is stimulated 169 
by stretch of the myocardium (27) and is considered a marker of cardiomyocyte hypertrophy 170 
(28). Its expression increases with gestation, as apparent in Hsd11b2+/+ fetuses (1.8 fold 171 
between E14.5 and E17.5, Fig 3D). However, neither Hsd11b2-/- nor Hsd11b2+/- fetuses showed 172 
this developmental increase in ANP expression in the heart. This suggests the Hsd11b2-/- fetal 173 
heart tissue is less compliant, as shown by ultrasound in vivo. Thus, overall Hsd11b2-/- fetuses 174 
show complex, gene-specific patterns of premature, exaggerated or reversed maturation of 175 
glucocorticoid-sensitive transcripts in the myocardium.  176 
 177 
Pravastatin increases labyrinth zone Vegfa expression and fetal capillary volume in all 178 
genotypes 179 
To determine if the adverse effects of glucocorticoid overexposure on the placental vasculature 180 
can be overcome and whether this might beneficially impact on fetal heart development, we 181 
administered (i.p.) either pravastatin or saline from E6.5 onwards with the aim of stimulating 182 
placental VEGFA production and thereby enhancing vascularization. Consistent with its 183 
reported effects on placental VEGF (23), pravastatin up-regulated expression of labyrinth zone 184 
Vegfa in all genotypes (Fig 4A). The increase in Hsd11b2-/- placentas was greater (genotype x 185 
treatment), eliminating the genotype difference in placental Vegfa expression. Despite its role 186 
in regulating Vegfa expression (29), labyrinth zone Pparg expression levels did not correspond 187 
with Vegfa patterns (Figure 4B); pravastatin had no effect on Pparg mRNA expression and a 188 
reduction in Pparg mRNA was apparent in both saline and pravastatin-treated Hsd11b2-/- 189 
placentas.  190 
 191 
Corresponding with increased placental Vegfa, placental weight increased with pravastatin 192 
(Table 1). Stereological assessment of labyrinth zone volume showed that while Hsd11b2-/- 193 
saline treated placentas appeared smaller this was not statistically significant (Fig 4C). 194 
Furthermore, there was only a trend (p=0.0536) for labyrinth zone volume increase with 195 
pravastatin (Fig 4C). Detailed investigation of fetal capillary volume provided a clearer insight 196 
into placental vascular development. Thus, pravastatin modestly increased the volume of fetal 197 
capillaries within the labyrinth zone of Hsd11b2+/+ and Hsd11b2+/- fetuses (Fig 4D) but 198 
completely rescued the deficit in Hsd11b2-/- placentas, with a significant interaction between 199 
treatment and genotype. There were no effects of pravastatin on maternal body weight, organ 200 
weight or litter size (Table S3). 201 
 202 
Pravastatin strikingly attenuates fetal growth restriction and reverses adverse umbilical 203 
flow and cardiac function in the Hsd11b2-/- placenta and fetus. 204 
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In saline-treated pregnancies, Hsd11b2-/- fetuses were lighter than littermate controls as 205 
previously reported (10) (Table 1). Pravastatin treatment increased fetal weight across all 206 
genotypes, though Hsd11b2-/- remained lighter than their Hsd11b2+/+ and Hsd11b2+/- 207 
littermates (Table 1). However, pravastatin ameliorated the growth retardation in Hsd11b2-/- 208 
fetuses such that they were the same weight as Hsd11b2+/+ controls.  209 
 210 
Pravastatin had a marked effect on placental blood velocity and fetal heart measures. Overall, 211 
pravastatin increased umbilical vein blood velocity (Fig 5A), decreased umbilical artery 212 
resistance index (Fig 5B) and increased fetal cardiac E/A wave ratio (Fig 5C) in all genotypes.  213 
Notably, pravastatin ‘normalised’ the aberrant phenotype of Hsd11b2-/- fetuses such that there 214 
were no genotype differences in umbilical vein blood velocity or fetal cardiac E/A ratio in 215 
Hsd11b2-/- fetuses from pravastatin-treated dams (Fig 5A and C). In contrast, the resistance 216 
index remained increased in both saline-treated and pravastatin-treated Hsd11b2-/- fetuses albeit 217 
to a lesser extent in the pravastatin-treated Hsd11b2-/- fetuses compared to saline treated (Fig 218 
5B). 219 
 220 
The effects of pravastatin on cardiac functional changes were not accompanied by gross 221 
morphological changes. Thus, there were no differences in overall cardiac volume, ventricular 222 
lumen volume or the ratio of ventricular wall thickness to lumen volume (Table S5).  223 
 224 
Pravastatin markedly alters fetal cardiac Ace and some collagen mRNAs 225 
Expression of glucocorticoid-responsive Tsc22d3 mRNA was not altered by pravastatin (Fig 226 
6A), consistent with increased glucocorticoid exposure and reflecting similar findings from the 227 
initial untreated cohort at E17.5 (Fig 3A). Therefore, the alterations in Hsd11b2-/- fetal heart 228 
function are likely independent of direct cardiac glucocorticoid action. Similarly, expression of 229 
Mhyc6 and Atp2a2 were unaffected by pravastatin in all genotypes (Fig 6B and C). While there 230 
was no effect of pravastatin on cardiac Nppa expression in Hsd11b2+/+ fetuses (Fig 6D), it 231 
increased in pravastatin-treated Hsd11b2-/- and Hsd11b2+/- fetuses. Thus, pravastatin- rescued 232 
cardiac Nppa expression in Hsd11b2+/- and partially rescued Hsd11b2-/- fetuses. Expression of 233 
Ace was decreased in fetal hearts of all genotypes with pravastatin (Fig 6E) abolishing the 234 
genotype difference seen in saline-treated fetuses.   235 
Collagen is a key contributor to cardiac wall stiffness. In fetuses from saline-treated dams, there 236 
was an increase in the cardiac expression of Col1a1 (which determines rigidity (30)) in 237 
Hsd11b2-/- and Hsd11b2+/- fetuses, compared to Hsd11b2+/+ littermates (Fig 6F). This 238 
difference was not evident in fetuses from pravastatin-treated dams. Col3a1 (which determines 239 
elasticity (30) showed a reciprocal effect; Col3a1 mRNA levels were reduced in hearts of 240 
saline-treated Hsd11b2-/- and Hsd11b2+/- fetuses compared to wild-type littermates (Fig 6G). 241 
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However, whilst pravastatin had no effect in Hsd11b2+/+, it increased Col3a1 mRNA levels in 242 
Hsd11b2-/- and Hsd11b2+/- fetuses. These expression patterns correspond with the changes in 243 
cardiac function. For Col4a1 (Figure 6H) there was no effect of genotype or treatment, but a 244 
significant interaction. Thus, pravastatin increased Col4a1 expression in hearts of Hsd11b2+/+ 245 
fetuses by 8.5-fold, but decreased it in Hsd11b2-/- fetuses (68% decrease). Pravastatin did not 246 
alter Vegfa and Pparg in the fetal heart. These data demonstrate that while pravastatin does not 247 
reverse cardiac glucocorticoid overexposure in Hsd11b2-/- fetuses, it does change key collagens 248 
and other endocrine genes in a pattern which corresponds with enhancement of Hsd11b2-/- fetal 249 
heart function.  250 
 251 
DISCUSSION 252 
Pravastatin treatment dramatically ameliorates the adverse phenotype of Hsd11b2-/- fetuses; 253 
placental labyrinth zone morphology, umbilical blood velocity, fetal weight and fetal heart 254 
function and gene expression are, for the most part, normalised. Thus, despite persistently 255 
increased placental and fetal glucocorticoid exposure in Hsd11b2-/- fetuses it is possible to 256 
counter these adverse outcomes, including the “intra-uterine growth restriction” (IUGR) 257 
phenotype. These findings highlight the crucial role of the placenta in informing fetal 258 
development and suggest statins as a potential therapy for IUGR with placental vascular 259 
insufficiency. 260 
 261 
Despite the ‘maturational’ effects of antenatal glucocorticoids we surprisingly found that 262 
Hsd11b2-/- fetuses exhibit delayed or impaired cardiac functional maturation. Whether these 263 
changes in fetal heart function alter cardiac function in adulthood will be important to uncover 264 
in the future, though in this experimental model adult heart function is likely to be influenced 265 
by the effect of life-long absence of 11β-HSD2 upon salt regulation, blood pressure and renal 266 
function (31), confounding interpretation. Pravastatin treatment then eradicated the impaired 267 
Hsd11b2-/- fetal cardiac maturation in conjunction with normalizing placental vascular 268 
parameters. We postulate that placental and umbilical cord haemodynamics could be an 269 
important factor directly influencing fetal heart development. Intervention is required to 270 
demonstrate this. However, recent evidence supports the view that the placenta directly 271 
influences the development of specific fetal organs, notably the heart. Thus, human placental 272 
size and shape are epidemiologically associated with the incidence of cardiovascular disease in 273 
later life (17, 32, 33). Thornburg et al. proposed (34) that because the fetal heart beats directly 274 
against the resistance of the placental bed, changes in placental blood velocity must impact on 275 
fetal heart development. Placental insufficiency (albeit severe – with absent or reversed 276 
diastolic velocity in the umbilical artery) results in increased loading of the right ventricle (19). 277 
Importantly, extensive work in genetically modified mouse models has revealed the necessity 278 
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of a functional placenta for optimal heart development; the cardiac defects exhibited in Pparγ 279 
and p38α null embryos are rectified by targeted placental normalisation (21, 22, 35). 280 
Furthermore, mice with genetic disruption of HOXA13, which is not expressed in the heart but 281 
is an important transcriptional regulator of placental Tie2 (and thus placental vascular 282 
branching) show abnormal placental endothelium which is associated with reduced ventricular 283 
wall thickness in the fetal heart (20), presumably occurring secondarily to the placental defect.  284 
 285 
Pravastatin, an HMG-CoA reductase inhibitor which reduces cholesterol biosynthesis, is 286 
currently contraindicated in pregnancy. This is due to its potential effects in altering NO 287 
bioavailability in the fetal circulation, with detrimental consequences for the fetal brain sparing 288 
response to acute hypoxia, as may happen intra-partum (38). However, pravastatin in various 289 
mouse models of preeclampsia appears to ameliorate preeclamptic pathology (23, 39), and 290 
pravastatin is currently the subject of a randomized control trial to ameliorate severe 291 
preeclampsia (40). Three biological compartments are exposed to pravastatin in our model: 1) 292 
the maternal, although our experimental design controls for alteration in maternal physiology 293 
as all fetal genotypes are generated within the one pregnancy, 2) the placental and 3), the fetal. 294 
Restoration of vasculogenesis in preeclamptic placentas following pravastatin has been 295 
variously attributed to stimulation of placental VEGF release, soluble Flt-1 (sFlt-1; a VEGF 296 
receptor), and placental growth factor (39, 41). Here, pravastatin enhanced labyrinth zone Vegfa 297 
expression in all genotypes. Accordingly, fetal capillary volume, umbilical vein velocity and 298 
umbilical resistance index underwent corresponding changes. Pravastatin will doubtless have 299 
placental actions beyond Vegfa. Indeed in human first trimester placental explants, pravastatin 300 
inhibits insulin-like growth factor 1 receptor function with adverse implications for trophoblast 301 
differentiation (42). With regard to the fetus, the levels of pravastatin achieved within the fetal 302 
circulation in this current study are unknown but earlier studies have demonstrated that transfer 303 
of pravastatin in ex vivo human placenta does occur albeit to a limited extent (43, 44). However, 304 
it is of interest to note that we observed no induction of Vegfa expression in Hsd11b2-/- fetal 305 
heart, suggesting that if pravastatin is eliciting direct effects on the fetus it may be via different 306 
pathways. Whilst we cannot discount the potential for direct effects of pravastatin on the fetus, 307 
the intriguing possibility is thus raised that the changes in cardiac parameters are primarily due 308 
to effects of pravastatin on enhancing the placental vasculature, with effects on the fetal heart 309 
occurring secondarily. 310 
 311 
Further specific investigations are required to dissect this potential placenta-cardiac axis. 312 
Placenta-specific removal of Hsd11b2 and manipulation of VEGFA specifically in the placenta 313 
will be useful to determine how placental vasculature impacts on fetal heart development and 314 
function. Nevertheless, our findings suggest the intriguing possibility that using extrinsic 315 
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factors to enhance placental vasculature in compromised pregnancies could have beneficial 316 
impact on fetal heart development and in IUGR more generally. Indeed, other gestational 317 
insults, such as fetal hypoxia, which also cause IUGR and cardiovascular programming can be 318 
overcome by administration of vitamin C (36, 37). However, the mechanism is likely different; 319 
while oxidative stress was attenuated by vitamin C, placental labyrinth zone volume remained 320 
unaltered (36, 37). 321 
 322 
Overall, these data add to the growing body of evidence that placental vasculature has a key 323 
role in fetal development and programming outcomes. Moreover, enhancement of placental 324 






Male and female Hsd11b2+/- mice, congenic on the C57BL/6J background (45), were mated 331 
overnight and the morning of the day the vaginal plug was identified was designated E0.5. The 332 
resultant pregnancies were only analysed if each of the possible offspring genotypes was 333 
represented in the litter: Hsd11b2+/+ (“control” littermates), Hsd11b2+/- and Hsd11b2-/-.  This 334 
approach controls for alteration in maternal physiology as all fetal genotypes are generated 335 
within the one pregnancy. Animals were given standard chow, water and housing arrangements 336 
and all studies were conducted in the strictest standards of humane animal care under the 337 
auspices of the UK Home Office Animals (Scientific Procedures) Act, 1986  and local ethical 338 
committee approval.   339 
 340 
Two groups of dams were utilized for this study. Group 1 underwent characterization of 341 
changes in placental and umbilical blood velocity and fetal heart development over gestation. 342 
A subset of Group 1 dams underwent ultrasound analyses at E14.5 or E17.5 (n = 8 at each time-343 
point). Following imaging, the pregnant dam was euthanized in situ, and scanned fetuses 344 
excised following identification by corroboration of position with the ultrasound images. 345 
Fetuses were fixed and umbilical cords were collected for subsequent myography studies. 346 
Placental and fetal tissues were collected from a further subset of dams (n = 8 at each timepoint) 347 
for gene expression analysis. 348 
 349 
Group 2 were injected with either saline (Sal) or 20 g/kg of pravastatin sodium salt (Prav; 350 
Cayman Chemical, Cambridge, UK) i.p. daily from E6.5 onwards. At E17.5, a subset 351 
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underwent ultrasound analyses and placentas were collected for stereological analysis (n = 8) 352 
whilst an additional cohort (n = 6 – 8) was generated for placental and fetal gene analysis.  353 
 354 
Umbilical cords were placed in ice-cold Krebs-Henseleit solution prior to subsequent 355 
myography studies. For RNA extractions, placentas were dissected rapidly over wet ice and 356 
separated into junctional and labyrinth zones before freezing on dry ice. Fetal hearts were 357 
dissected and immediately frozen on dry ice. For histological investigations, whole placentas, 358 
umbilical cords and fetuses were fixed in formalin and paraffin embedded. Fetal tails were 359 
collected in all cases for genotyping and gendertyping by PCR as described (10). However sex 360 
was not taken into account in the final analyses due to an insufficient number of each sex for 361 
each possible genotype to reach statistical power. 362 
 363 
High resolution ultrasound analysis 364 
In vivo ultrasound assessment was performed using a Vevo 770 ultrasound biomicroscope 365 
(Visualsonics; Toronto, Canada) using a RMV707B 30MHz centre frequency transducer. 366 
Pregnant mice were scanned as described (26). Fetal-placental units were imaged over a strict 367 
20 min time period, with a minimum of three units being analysed in each pregnancy. Blood 368 
velocity within the umbilical artery, vein and placenta was measured (46). Fetal hearts were 369 
visualized in B-mode and Doppler measurements were undertaken to determine the E/A wave 370 
ratio and myocardial performance index (MPI) (26). Images were recorded for offline analysis. 371 
 372 
Placental and umbilical cord morphology 373 
Placental stereological investigations were conducted as described (10). Umbilical cord 374 
morphology was ascertained from four cross-sectional haemotoxylin and eosin stained sections 375 
taken from the midline of the umbilical cord, 80 μm apart. The umbilical artery and vein area 376 
and perimeter were calculated by manually tracing the outer smooth muscle outline and lumen 377 
perimeter using Nikon NIS Elements Imaging Software v4.10. (Nikon Instruments Inc., 378 
U.S.A.). All measurements were performed by an observer blind to genotype. Treatment and 379 
intra-observer error was less than 5%. 380 
 381 
Cardiac morphology 382 
Serial haemotoxylin and eosin stained sections were assessed using Nikon NIS Elements 383 
Imaging Software v4.10. (Nikon Instruments Inc., U.S.A.). Cardiac tissue volume and 384 
cardiomyocyte number were determined using stereological investigations as described (47). 385 
Ventricle wall thickness was assessed by measuring the thickness of the wall at the point 386 
perpendicular from the center of the longest axis of the ventricle. 387 
 388 
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Umbilical vessel myography  389 
The contractile and vasodilator capacity of umbilical vessels was assessed by myography, based 390 
on modifications of previously established protocols. Umbilical arteries were carefully 391 
dissected, cut into lengths of ~1.5 mm, then mounted on a wire myograph (610M; Danish Myo 392 
Technology, Aarhus, Denmark) using 25 μm diameter wire. Vessels were placed at 2 mN 393 
pretension, allowed to equilibrate for 30-60 min, before establishing vessel viability with high 394 
K+ physiological saline solution (K+PSS)+noradrenaline (10 μM). Arteries with a contraction 395 
of 1 mN or less were excluded from the analysis). Vessels were contracted with increasing 396 
doses of thromboxane mimetic (U46619). EC80 concentrations of U46619 were chosen to 397 
precontract arteries, before carrying out concentration response curves to the endothelium-398 
dependent vasodilator, acetylcholine (ACh), and the endothelium-independent vasodilator, 399 
sodium nitroprusside (SNP). To assess basal endothelial activity, vessels were partially 400 
precontracted with EC50 U46619, before addition of the eNOS inhibitor, Lω-nitro-L-arginine 401 
methyl ester (L-NAME; 200 μM), and the cyclooxygenase (COX) inhibitor, indomethacin (10 402 
μM). The data from force transducers were processed by a MacLab/4e analogue-digital 403 
converter and displayed through Chart software, version 3.4.3 (AD Instruments, Sussex, UK).  404 
 405 
Quantitative qPCR 406 
Total RNA was extracted from tissue using QIAzol® Lysis reagent (Qiagen Sciences, Victoria, 407 
Australia) as per the manufacturer's instructions. Total RNA (1 μg) was reverse transcribed 408 
using Mouse Moloney leukemia virus reverse transcriptase (M-MLV) and random primers 409 
(Promega, Sydney, Australia). The cDNA was subsequently purified with Ultraclean PCR 410 
Cleanup kit (MoBio Laboratories, Inc., Carlsbad, CA).  411 
 412 
Specific mRNA levels were measured by quantitative (q)RT-PCR on the Rotorgene 6000 413 
system (Corbett Research, Sydney, Australia) using QuantiTect SYBR Green Mastermix 414 
(Qiagen Sciences, Victoria, Australia). Primers for Vegfa, peroxisome proliferator-activated 415 
receptor gamma (Pparg), glucocorticoid-induced leucine zipper (GILZ, for Tsc22d3), myosin 416 
heavy chain 6 alpha (Myh6), sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (Atp2a2), 417 
natriuretic peptide A (Nppa), angiotensin I converting enzyme (Ace), collagen, type I, alpha 1 418 
(Col1a1), collagen, type III, alpha 1 (Col3a1), collagen, type IV, alpha 1 (Col4a1) were 419 
purchased as Qiagen QuantiTect primers with the exception of the internal standards, Tbp, Ppia 420 
and Sdha, which were designed using Primer-BLAST (http://www.ncbi.nlm.nih.gov). Primer 421 
pairs for all genes are listed in Table S4. Standard curves were generated through tenfold serial 422 
dilution of purified PCR products for each gene with analysis using Rotorgene 6000 Software. 423 
All samples were normalized against Tbp, Sdha and Ppia using the GeNorm algorithm (48). 424 
 425 
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Statistical analysis 426 
All data are expressed as mean ± SEM, with each litter representing n = 1, with no more than 427 
1 representative pup per litter analysed. For fetal and placental weights, n = 14-20. Fetal sex 428 
was noted but was not taken into account in analyses, including fetal weight, as statistical power 429 
was insufficient for analysis by gender as well as genotype. For ultrasound (n = 8) values were 430 
normalized to fetal weight. For heart and umbilical cord morphology and gene expression 431 
studies, n = 6–8. Two-way ANOVA followed by Tukey’s post hoc test or one-way ANOVA 432 
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Tables 568 
Table 1:  E17.5 fetal and placental weights of Hsd11b2+/+, Hsd11b2+/- and Hsd11b2-/- fetuses 569 
from saline (Sal) or pravastatin-treated (Prav) dams. 570 
 571 
 Sal (n=28) Prav (n=32) 














0.09±0.02a 0.08±0.03a 0.1±0.03b 0.1±0.03b 0.1±0.04b 
Values are the mean ± SEM. Values without common notation differ significantly (p<0.05, 572 
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Figure Legends 581 
 582 
Figure 1: Umbilical vein velocity (A), umbilical artery resistance index (B) and fetal cardiac 583 
E/A wave ratio (C) in Hsd11b2+/+, Hsd11b2+/- and Hsd11b2-/- fetuses at E14.5 and E17.5. Values 584 
were normalized for fetal weight and are the mean ± SEM (n = 8 per group). Columns without 585 
common notation differ significantly (p<0.05, two-way ANOVA, Tukey’s post hoc test).  586 
 587 
Figure 2: Contractile and vasodilator function of umbilical arteries. (A) H&E stained cross-588 
section of the umbilical cord. Scale bar = 100 μm. Inset, higher magnification of the umbilical 589 
artery used for myography studies. Arrows indicate the presence of endothelial cell nuclei on 590 
the lumenal surface of the artery. (B) Maximal contraction of arteries to high potassium 591 
physiological saline solution containing noradrenaline (K+PSS+NA) in animal with disrupted 592 
Hsd11b2 alleles. (C) Maximum vasodilator response to the thromboxane mimetic U46619 in 593 
umbilical arteries from Hsd11b2-/- fetuses (*P<0.05, unpaired t-test of Kmax). (D) Contractile 594 
response to inhibition of basal endothelium-dependent relaxation in response to Lω-nitro-L-595 
arginine methyl ester (L-NAME) and indomethacin (**P<0.01, unpaired t-test). (E) 596 
Vasodilator response to sodium nitroprusside (SNP). For B, C & E, data shown are the mean ± 597 
SEM (n=6, 20, 9 for Hsd11b2+/+, Hsd11b2+/-. Hsd11b2-/-, respectively). For D, data shown are 598 
the mean ± SEM (n=5, 11, 8 for Hsd11b2+/+, Hsd11b2+/-. Hsd11b2-/-, respectively). 599 
 600 
Figure 3: Relative levels of (A) Tsc22d3, (B) Myh6, (C) Atp2a2 and (D) Nppa mRNA in hearts 601 
of Hsd11b2+/+, Hsd11b2+/- and Hsd11b2-/- fetuses at E14.5 and E17.5. Values are means ± SEM 602 
(n = 6-8 per group). Columns without common notation differ significantly (p<0.05, two-way 603 
ANOVA, Tukey’s post hoc test).  604 
 605 
Figure 4: Placental gene expression and morphology in control and pravastatin treated 606 
Hsd11b2+/+, Hsd11b2+/- and Hsd11b2-/- fetuses.  (A) Relative labyrinth zone Vegfa mRNA 607 
expression and (B) Pparg mRNA expression, (C) labyrinth zone (LZ) fraction and (D) fetal 608 
capillary (FC) volume. Values are the mean ± SEM (n = 6-8 per group). Columns without 609 
common notation differ significantly (p<0.05, two-way ANOVA, Tukey’s post hoc test). Sal, 610 
Saline-treated; Prav, Pravastatin-treated, LZ, labyrinth zone; FC, fetal capillaries. 611 
 612 
Figure 5: Umbilical vein velocity (A), umbilical artery resistance index (B) and fetal cardiac 613 
E/A wave ratio (C) in saline and pravastatin treated Hsd11b2+/+, Hsd11b2+/- and Hsd11b2-/- 614 
fetuses. Values were normalized for fetal weight and are the mean ± SEM (n = 8 per group). 615 
Columns without common notation differ significantly (p<0.05, two-way ANOVA, Tukey’s 616 
post hoc test). Sal, Saline-treated; Prav, Pravastatin-treated. 617 
 20 
 618 
Figure 6: Fetal cardiac gene expression in control and pravastatin treated Hsd11b2+/+, 619 
Hsd11b2+/- and Hsd11b2-/- fetuses.  Relative levels of (A) Tsc22d3, (B) Myh6, (C) Atp2a2, (D) 620 
Nppa, (E) Ace, (F) Col1a1, (G) Col3a1 and (H) Col4a1. Values are the mean ± SEM (n = 6-8 621 
per group). Columns without common notation differ significantly (p<0.05, two-way ANOVA, 622 
Tukey’s post hoc test). In the case of Col4a1 *p<0.05, t-test of corresponding genotype between 623 
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Figure 2  631 
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Figure 3 634 
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Supporting Information 651 
 652 
Table S1: Myocardial performance index of Hsd11b2+/+, Hsd11b2+/- and Hsd11b2-/- fetuses at 653 
E14.5 and E17.5. Values without common notation differ significantly. 654 
 655 
 E14.5 E17.5 
 Hsd11b2+/+ Hsd11b2+/- Hsd11b2-/- Hsd11b2+/+ Hsd11b2+/- Hsd11b2-/- 
MPI 0.75±0.05a 0.75±0.02 a 0.72±0.03 
a 
0.63±0.03 b 0.64±0.02 b 0.65±0.03 
b 
IVCT (ms) 22±0.3 a 23.4±0.1 a 22.8±0.2 a 18.1±0.2 b 16.9±0.4 b 19.6±1 b 
ET (ms) 101.4±5 97.3±3 105.6±5 105.3±2 98.6±5 102.6±4 
IVRT (ms) 26.1±3 a 24.8±2 a 25.9±3 a 22.4±3 b 20.1±1 b 21.7±0.5 b 
EDD  
(mm/s2) 
1542±481 a 1329±312 a 1376±548 
a 
3128±682 b 3308±384 b 1365±445 
a 
EF (%) 73.8±3.5 a 76.2±2 a 71.8±1.4 a 85.2±2.1 b 81.3±1.9 b 82.6±1.5 b 
       
Values are the mean ± SEM. MPI, myocardiacl performance index; IVCT, isovolumetric 656 
contraction time; ET, ejection time; IVRT, isovolumetric relaxation time; EDD, early 657 
diastolic deceleration; EF, ejection fraction 658 
 659 
 660 
Table S2: Lumen and vessel wall area of umbilical arteries and vein from Hsd11b2+/+ and 661 
Hsd11b2-/- fetuses. 662 
 Umbilical artery Umbilical vein 
 Hsd11b2+/+ Hsd11b2-/- Hsd11b2+/+ Hsd11b2-/- 
Lumen area 
(μm2) 
4211±1265 3624±986 36211±8246 29425±6937 
Vessel wall 
area (μm2) 
32646±1324 28436±2534 24328±879 18656±2289 
Values are the mean ± SEM 663 
  664 
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Table S3: Pravastatin treatment does not affect maternal body weight, organ weight or litter 665 
size. 666 
 Sal (n=28) Prav (n=32) 
E17.5 maternal weight (g) 31.7±1.7 32.0±1.9 
Brain weight (g) 0.46±0.01 0.47±0.01 
Liver weight (g) 1.63±0.07 1.8±0.06 
Heart weight (g) 0.15±0.01 0.18±0.01 
Left kidney weight (g) 0.15±0.01 0.15±0.01 
Litter size 8.1±0.8 9.1±0.5 
Values are the mean ± SEM. Sal, Saline-treated dams; Prav, Pravastatin-treated dams. 667 
 668 
 669 
Table S4: PCR conditions 670 











Col1a1 QT 00162204 
Col3a1 QT 01055516 
Col4a1 QT 00287392 
Col5a1 QT 01055474 
Sdha F, 5’-TGGGGCGACTCGTGGCTTTC- 3′ 
 R, 5’-CCCCGCCTGCACCTACAACC- 3′ 
Ppia F, 5’-AGCATACAGGTCCTGGCATC- 3′ 
 R, 5’-TTCACCTTCCCAAAGACCAC- 3′ 
Tbp F 5’ GGGAGAATCATGGACCAGAA ‘3 
R 5’ CCGTAAGGCATCATTGGACT ‘3 
Qiagen QuantiTect primer name and primer sequences for analysis and reference genes. F, 671 
forward; R, reverse. 672 
 673 
 674 
  675 
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Table S5: Pravastatin treatment does not alter overall cardiac volume, ventricular lumen 676 
volume or the ratio of ventricular wall thickness to lumen volume of Hsd11b2+/+, Hsd11b2+/-, 677 
and Hsd11b2-/- fetuses. 678 
 Sal Prav 






















0.42±0.05 0.39±0.04 0.44±0.06 0.43±0.02 0.41±0.03 0.41±0.04 
Values are the mean ± SEM. Sal, Saline-treated; Prav, Pravastatin-treated; LV, left ventricle; 679 
RV, right ventricle 680 
 681 
  682 
 30 
Figure S1: Acetylcholine (ACh) did not relax umbilicial arteries. There were no significant 683 
differences between genotypes. Symbols shown are mean±SEM (n=6, 12 & 9 for Hsd11b2+/+, 684 
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